ArticleFrontiers in cardiovascular medicine2026
Identification of novel and known variants in
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The etiology of CAD is multifactorial, involving a complex interplay of genetic, environmental, and lifestyle factors, and CAD markedly increases the likelihood of impaired quality of life. Aim: To identify potentially impactful genetic variants in patients with CAD that may influence the risk, severity, and clinical outcomes of the condition, we performed whole exome sequencing (WES) in 28 patients. Diverse risk factors such as gender and clinical conditions, including hypertension, hyperlipidemia, obesity, and T2DM, which are known contributors to cardiovascular adversities, have been found to be present in a significant proportion of the patients. Results: Our study identified 13,289 variants in 108 genes across the cohort, with a median of 545 per patient. The most frequently mutated genes were TTN, followed by GAA, SVIL, NRAP, and DMD, all of which are related to sarcomere structural and functional integrity and cardiomyopathies. Analysis of VEP impact identified 341 variants in 58 genes with 122 novel variants (36%) not previously reported in public databases. The variants were classified as missense (66%), followed by frameshifts (25%) and in-frame indels (5%), with a minor proportion (4%) of nonsense, splice-site, and other protein-altering variants. Among these 58 genes, TTN emerged as the most frequently mutated gene, present in 96% of patient samples, while the other substantially mutated genes in patients included FLNC (29%), AGL (25%), ALPK3 (21%), and DSP (21%). A comprehensive analysis of candidate variants identified 21 variants classified as either pathogenic (3) or likely pathogenic (18), which may play a significant role in the development of cardiovascular disease. These variants met the American College of Medical Genetics and Genomics (ACMG) criteria for PM2 classification, indicating a very low (<1%) or absent frequency in population databases. Among these, eight variants were novel and classified as likely pathogenic, reported in genes GAA, MYH6, NEXN, ATA3A, RHBDF1, and ACTA1. Most gene variants have functional significance in cardiovascular pathologies, as demonstrated by gene ontology and human phenotype ontology enrichment analyses reported in this study. Conclusion: The study has utilized whole exome sequencing to identify both known and novel gene variants that may contribute to disease risk, facilitating a deeper understanding of the genetic landscape of CAD. This high-resolution approach allows the detection of pathogenic and likely pathogenic variants in critical genes associated with cardiovascular health and provides evidence of functional significance, thereby elucidating complex interactions between genetic factors and enhancing understanding of disease mechanisms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.